Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia

NCT ID: NCT00260819

Last Updated: 2008-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-01-31
• Study Completion Date: 2008-04-30

Brief Summary

Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of the factors implicated in high-altitude pulmonary oedema. Plasma ET1 increases in subjects exposed to high altitude and is correlated to pulmonary artery pressure.

The aim of the study is to investigate whether blockade of ET1 receptors would reduce the acute rise in systolic pulmonary artery pressure induced by hypoxia.

Detailed Description

Patients will be examined on a variable load supine bicycle ergometer. The exercise table will be tilted laterally by 20 to 30 degrees to the left. PASP will be assessed using Doppler echocardiography at rest and during during supine bicycle exercise in NORMOXIA and hypoxia. Exposure to normobaric hypoxia will be performed by breathing a hypoxic gas mixture at sea level during 90 minutes (12,3 % O2 + 87.7 % N2) reproducing conditions at 4300 m altitude. Exercise will be started at an initial workload of 40 watts and increased by 10 watts every minute to reach a workload level defined by a heart rate (HR) corresponding to 50% of the estimated maximal aerobic power

Conditions

Hypoxia-Induced Pulmonary Artery Hypertension

Keywords

Hypoxia-induced pulmonary artery hypertension; High-altitude pulmonary oedema; ETA receptor antagonist

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Experimental and Placebo Comparator administered in random order during to successive experimental phase

Group Type: EXPERIMENTAL

Bosentan

Intervention Type: DRUG

Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

2

Experimental and Placebo Comparator administered in random order during to successive experimental phase

Group Type: PLACEBO_COMPARATOR

Bosentam TRACLEER

Intervention Type: DRUG

Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

Interventions

Bosentan

Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

Intervention Type: DRUG

Bosentam TRACLEER

Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

Intervention Type: DRUG

Other Intervention Names

TRACLEER

Eligibility Criteria

Inclusion Criteria

• 20 non smoker healthy volunteers : 10 resistant to high-altitude pulmonary oedema and 10 susceptible subjects, without history of cardiac or pulmonary disease or asthma, after a complete clinical examination and safety laboratory measurements prior to randomization, and after giving informed written consent.

Exclusion Criteria

• antecedent of lung disease notably with asthmatic antecedent or HTAP
• antecedent of heart disease
• female genital organ
• systolic blood pressure < 85 mmHg or > 160 mmHg after 5 minutes of lengthened rest.
• sentimentality in a medicine, in particular in a bosentan or in one of the excipients of the tablet.
• hepatic incapacity moderated to severe correspondent in the class B or C of the classification of Child-Pugh (cf Pharmacokinetics) Rate serous hepatic aminotransferases, aspartate aminotransferases( ASAT) and\or alanine aminotransférases ( ALAT), superior to 3 times the superior limit of the normal before the started of the treatment.
• pointed or chronic systematic diseases.
• presence of antibody anti-HIV, of anti-HVC antibody, antigens Hbs and\or antibody anti-Hbc. - active addiction to smoking.
• alcohol abuse and of toxins.
• Taking of concomitant medicines except those allowed the chapter concomitant treatments.
• signs, symptoms or values of the biological examinations situated except the clinically acceptable values for healthy subjects with or without antecedent of OPHA.
• common(current) ingestion of excessive quantities of tea, coffee(cafe), chocolate and\or drinks containing some caffeine (> 5 cups / day, is approximately 500 mg of caffeine a day).
• consumption of juice of grapefruit and\or herb tea on base of St.
• John's wort
• Don of blood in 3 months preceding the study.
• Persons in period of exclusion on the national file of the persons lending itself to the biomedical search(research) without direct individual profit.
• refusal or linguistic or psychic incapacity to sign the lit(enlightened) assent.
• subject which can not submit itself to the constraints of the protocol (for example, not cooperative, incapable to go(surrender) to the visits of follow-up and probably incapable to finish the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Department Clinical Research of Developpement

Principal Investigators

Michel AZIZI, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou

Paris, , France

Countries

France

References

Grunig E, Mereles D, Hildebrandt W, Swenson ER, Kubler W, Kuecherer H, Bartsch P. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol. 2000 Mar 15;35(4):980-7. doi: 10.1016/s0735-1097(99)00633-6.

Reference Type: RESULT

PMID: 10732898 (View on PubMed)

Other Identifiers

AOR05038

Identifier Type: -

Identifier Source: secondary_id

P050502

Identifier Type: -

Identifier Source: org_study_id